Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 8/2016

01-08-2016 | Head and Neck

Influence of allelic variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab

Authors: Carmen Muñoz, Miguel Caballero, Sofia Hakim, Eugenia Verger, Juan Jose Grau

Published in: European Archives of Oto-Rhino-Laryngology | Issue 8/2016

Login to get access

Abstract

Although cetuximab plus radiotherapy is a standard treatment for patients with inoperable head and neck squamous cell carcinoma (HNSCC), its efficacy varies greatly among individuals. To identify predictive markers of efficacy, we examined the effects of single nucleotide polymorphisms (SNPs) in hypoxia-related and DNA repair genes on the clinical outcome and occurrence of skin toxicity. We analyzed 61 consecutive patients with HNSCC for the presence of specific SNPs (HIF-1α, HIF-2α, HIF-1β, VHL, FIH-1, XRCC1, and XRCC5). The results were then correlated with time to progression (TTP), overall survival (OS), and toxicity (epithelitis, mucositis, and folliculitis). The median TTP and OS were better in patients with severe vs mild mucositis (17 vs 7 months, p = 0.03; and 26 vs 12 months, p = 0.016, respectively) and folliculitis (10 vs 7 months, p = 0.01, and 26 vs 10 months, p < 0.001, respectively). Patients with the HIF-1α CT/TT genotype had better OS than those with the wild-type HIF-1α CC genotype (28 vs 13 months, p = 0.035). Patients with the XRCC5 GG/AA genotype had longer TTP than patients with the XRCC5 AG genotype (11 vs 7 months, p = 0.035). Severe skin toxicity and SNPs of HIF-1α and XRCC5 were associated with different outcomes among patients treated with radiotherapy plus cetuximab.
Literature
1.
Pfister DG, Ang KK, Brizel DM et al (2011) Head and neck cancers. J Natl Compr Canc Netw 9(6):596–650PubMed
2.
Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28CrossRefPubMed
3.
Mukherjee B, Choy H, Nirodi C, Burma S (2010) Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. Semin Radiat Oncol 20:250–257CrossRefPubMedPubMedCentral
4.
5.
Alsbeih G, El-Sebaie M, Al-Harbi N, Al-Hadyan K, Shoukri M, Al-Rajhi N (2013) SNPs in genes implicated in radiation response are associated with radiotoxicity and evoke roles as predictive and prognostic biomarkers. Radiat Oncol 8:1–7CrossRef
6.
Bussink J, van der Kogel AJ, Kaanders JH (2008) Activation of the PI3K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9:288–296CrossRefPubMed
7.
Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M (2007) Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10:81–100CrossRefPubMedPubMedCentral
8.
9.
Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832CrossRefPubMed
10.
Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N, Shimizu K, Grenman R, Nagai N (2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99:1589–1594CrossRefPubMed
11.
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311CrossRefPubMed
12.
Madshus IH, Stang E (2009) Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J Cell Sci 122:3433–3439CrossRefPubMed
13.
Bárdos JI, Ashcroft M (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26:262–269CrossRefPubMed
14.
15.
Brahimi-Horn C, Mazure N, Pouysségur J (2005) Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 17:1–9CrossRefPubMed
16.
Eisenhauer EA, Therasse P, Bogaert J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
17.
Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, Lonati V, Sarti E, Barni S (2014) Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol 50(11):1041–1048CrossRefPubMed
18.
Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, Vigo V, Bacigalupo A, Numico G, Crosetto N, Gasco M, Lo Nigro C, Vitiello R, Violante S, Garrone O (2011) Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol 22:712–717CrossRefPubMed
19.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck carcinoma: rTOG 0522. J Clin Oncol 20(32):2940–2950CrossRef
20.
Carles J, Monzo M, Amat M et al (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I–II head and neck cancer. Int J Radiat Oncol Biol Phys 66:1022–1030CrossRefPubMed
21.
El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, Bignon YJ (2011) Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One 6:e25080CrossRefPubMedPubMedCentral
22.
Reiter M, Welz C, Baumeister P, Schwenk-Zieger S, Harréus U (2010) Mutagen sensitivity and DNA repair of the EGFR gene in oropharyngeal cancer. Oral Oncol 46:519–524CrossRefPubMed
23.
Muñoz-Guerra MF, Fernández-Contreras ME, Moreno AL, Martín ID, Herráez B, Gamallo C (2009) Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol 16:2351–2358CrossRefPubMed
24.
Wang X, Schneider A (2010) HIF-2a-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31:1202–1210CrossRefPubMedPubMedCentral
25.
Kriegs M, Kasten-Pisula U, Rieckmann T et al (2010) The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair 9:889–897CrossRefPubMed
Metadata
Title
Influence of allelic variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab
Authors
Carmen Muñoz
Miguel Caballero
Sofia Hakim
Eugenia Verger
Juan Jose Grau
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 8/2016
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-015-3740-4

Other articles of this Issue 8/2016

European Archives of Oto-Rhino-Laryngology 8/2016 Go to the issue

Head and Neck

Nasopharyngeal carcinoma with intracranial extension in the era of intensity-modulated radiotherapy: case–control study using propensity score matching method

Head and Neck

Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey

Laryngology

Prospective analysis of functional swallowing outcome after resection of T2 glottic carcinoma using transoral laser surgery and external vertical hemilaryngectomy

Letter to the Editor

Training model for endoscopic sinus surgery using lamb’s head

Otology

The effect of the transducers on paediatric thresholds estimated with auditory steady-state responses

Head and Neck

Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status